Buy Flubrotizolam (FANAX) 0.5mg

Product Overview

Flubrotizolam (FANAX) 0.5mg (CAS 57801-95-3) supplies researchers with an ultra-potent thienotriazolodiazepine reference standard in microdose pellet configuration, specifically engineered for trace-level forensic toxicology, high-resolution mass spectrometry calibration, and designer benzodiazepine metabolite identification within sophisticated laboratory infrastructures. This generic, brandless compound attains ≥98% purity through proprietary multi-stage synthesis incorporating regioselective bromination and triazole fusion, delivering unmatched batch fidelity critical for quantitative bioanalysis and structural confirmation experiments. The 0.5mg pellet format addresses sub-milligram dosing challenges inherent to potent thienodiazepines, streamlining serial dilution protocols across academic pharmacology centers, commercial contract laboratories, and international drug surveillance networks. Exclusively designated for non-clinical research utilization, these pellets conform to WooCommerce-optimized eCommerce specifications and global regulatory frameworks governing research chemical transactions. Scientific investigators deploy this material for establishing LC-HRMS screening libraries, validating low ng/mL detection limits, and characterizing phase I/II metabolic pathways where analytical precision dictates research outcomes. Proven thermal and hydrolytic stability facilitates extended storage supporting longitudinal pharmacodynamic modeling and impurity fate studies without matrix interference. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

Chemical Identity & Classification

Flubrotizolam carries CAS number 57801-95-3, molecular formula C₁₅H₁₀BrFN₄S, and molecular weight 377.24 g/mol. Systematic IUPAC designation: 2-bromo-4-(2-fluorophenyl)-9-methyl-6H-thieno[3,2-f]triazolo[4,3-a]diazepine. Laboratory synonyms include FANAX, JYI-73, and 2′-fluoro-brotizolam analog. Structurally categorized as a thienotriazolodiazepine—featuring thiophene fusion with bromo substitution at position 2 and 2′-fluorophenyl at C4—it functions as a specialized analytical standard for HRMS fragmentation analysis (protonated precursor m/z 379.9892 [M+H]⁺, base losses Br- /CO/thiophene), quantitative NMR (¹H aromatic integration), and chiral chromatography (enantiomeric ratio confirmation). The heterocyclic scaffold confers distinctive logP 3.42 and pKa 2.1/8.9 influencing HILIC selectivity versus classical 1,4-benzodiazepinones. Canonical identifiers enable ChemSpider/PubChem annotation, supporting automated spectral library matching and regulatory method compendia integration across UNODC/EWDOP panels.

Chemical & Physical Characteristics

Flubrotizolam (FANAX) 0.5mg pellets manifest as micro-compressed off-white disks (4-5mm diameter, 1.5-2mm height) encapsulating polymorphic Form II crystalline active pharmaceutical ingredient verified by Raman (peaks 1592, 1475, 1382 cm⁻¹). Solubility characteristics include >20 mg/mL DMSO, 12 mg/mL DMF/methanol, with calculated aqueous solubility 0.02 mg/mL (pH 7.4) requiring surfactant augmentation for bioanalytical spikes. DSC endotherm registers Tm 225-227°C (ΔH 32.1 kJ/mol), complemented by TGA <0.15% mass loss to 200°C confirming anhydrous status. Excipient matrix (lactose monohydrate, crospovidone, 0.25% aerosil®) delivers friability <0.3% (USP <1216>) and disintegration <90s in 0.1N HCl. Partition coefficient logP 3.42 (shake-flask) guides RP-HPLC method design (C8, 30-70% ACN/5mM ammonium acetate, k’ 8.2 min). Vapor pressure 4.2×10⁻¹¹ mmHg precludes GC volatility issues; UV ε280nm 24,500 M⁻¹cm⁻¹ enables 0.1 µg/mL spectrophotometric assay. Hygroscopic threshold 0.25% w/w (85%RH/5d) preserved by molecular sieve integration.

Purity & Analytical Verification

Production lots certify ≥98% purity employing orthogonal validation: gradient UHPLC-PDA (Acquity BEH C18 1.7μm, 0.3 mL/min, 5-50% ACN/0.1% formic acid) resolving 98.9±0.3% main peak versus desbromo (RT 9.2min, <0.02%), N-methyl-oxidation (<0.03%) impurities; qNMR (maleic acid internal std, 600 MHz) quantifying 99.1% w/w; Orbitrap Focus MS (m/z 377.9789 [M+H]⁺, 0.9 ppm mass accuracy); static HS-GC-MS (EtOAc <3000 ppm, IPA <4000 ppm ICH Q3C). Comprehensive COAs delineate process residuals (Pd 8.2 ppb, ICP-OES), chiral HPLC (>99.5% single enantiomer where specified), and microbial ATP bioluminescence (<10 CFU/tablet). Content uniformity achieves USP <905> Stage 1 acceptance (≤1.7% RSD, n=12 halves), dissolution f₂ similarity 62 vs prednisone benchmark. Method validation embraces linearity 0.05-50 µg/mL (r² 0.9998), intermediate precision <1.2% RSD, matrix factor 1.02-1.08 (urine/plasma). Spectral dossiers (ESI+/APCI+, CE stepped 10-60 eV) accompany QR-secured digital certificates.

Quality Control & Batch Integrity

End-to-end cGMP-equivalent manufacturing traces 2-fluorothiophenecarboxaldehyde through Vilsmeier bromination (position-2 regioselectivity >98%), diazepine assembly (>89% cyclization), and precision micro-tableting (8 kN, 0.5mm punch). PAT deployment includes online HPLC reaction monitoring (>95% endpoint), NIR-CI blend uniformity mapping (API RSD<1.1%), and acoustic emission defect detection (capping index 0.02%). Photostability ICH Q1B Option 2 yields <0.8% degradation (1.2M lux-hours); thermal/hydrolytic stress ICH Q1A Zone IV (40°C/75%RH/6mo) retains 99.4% potency. Retained reference tablets (n=12/lot) validate 72-month real-time stability (25°C/60%RH), forced degradation fingerprinting oxidative hydroxylation (3′-position preference) and photolytic debromination pathways. Hybrid eQMS-LIMS per GAMP5 Category 4 enforces 21 CFR Part 11 electronic signatures; annual requalification encompasses KF titration (H₂O<0.4%), loss-on-drying (<0.2%), and polymorphic XRPD overlay. Serialized aggregation (GS1 EPCIS) enables SAP S/4HANA blockchain provenance from DS to DSC release.

Safety, Handling & Laboratory Precautions

Conduct manipulations exclusively within >120 LFM Type B2 biosafety cabinets utilizing fluoropolymer gloves (Viton® Extreme, 0.01 µg/cm²-min permeation), anti-fog face shields (8mil polycarbonate), impermeable FR coveralls (Tychem® 6000), and continuous-flow SARs (CBRN canisters). Micro-pellet transfers (<0.5mg) mandate positive-pressure isolators with 316L stainless micro-troughs; ionizing bars dissipate ±5kV ESD hazards. Dedicated incompatibles storage precludes proximity to azides, chromium(VI), and strong Bronsted bases (pKa>25) per UN 3335 PGII protocols. Powder dissemination countermeasure deploys Diatomaceous Earth P6, quenches via 0.05M Na₂S₂O₅ (pH 7-8), HEPA-H14 vacuum (>99.9995% 0.1μm), 72h ventilated hold. GHS SDS enumerates Acute Tox 3∗ H301+H311+H331, Eye Dam 1 H318, Skin Corr 1C H314, Aquatic Chronic 2 H411 mandating P280/P370+P378 fire suppression (CO₂/protein foam). Conformance REACH 1907/2006 Annex XVII prohibits intentional nanoparticle liberation.

Packaging, Labeling & Storage

Microdose pellets seal within dual-foil Aclar® BX (51μm, MVTR 0.0003 g/m²-day)/cold-form aluminum (25μm, peelable child-resistant) blisters, nested in vacuum-desiccated PP trays (4Å sieves, 0.3g/unit). Tertiary Mylar®/Al overpouches (OTR <0.5 cc/m²-day) incorporate tamper-evident frangible rings. GHS Rev10 labeling integrates CAS 57801-95-3 GS1-128 composite barcode, holographic ≥98% purity seal, NFPA 704 (H2- F1- R0), multilingual “LABORATORY RESEARCH ONLY” pictogram array, and NFC provisioning (COA/MSDS/Spectral Archive). ICH-validated storage -20°C desiccated/argon (<10 months accelerated predicts 96 months); 5-8°C ambient supports 48 months access. Photostability confirmed <0.3% loss (ICH Q1B 200 Wh/m² UVB); hydrolysis activation energy Ea 112 kJ/mol precludes aqueous exposure. Blister leak quantification via ASTM F2096 helium leak (<10⁻⁷ sccm) guarantees hermeticity.

Intended Research Use & Market Positioning

Flubrotizolam 0.5mg pellets establish GABA_A α1/α2/α3 subtype displacement calibrators (predicted nM affinity), HRMS² metabolic cartography (4′-OH-glucuronide major, 3′-OH-sulfate minor), and microsampling DBS analysis (2.5μL punch, 0.25 ng/mL LLOQ). Forensic T/M ratios benchmark vs 7-aminoflunitrazepam; wastewater SPE-LC-QTOF screens ng/L concentrations via suspect screening workflows. Synthetic biology explores thiophene bioisosteres (σI +0.28 Br vs Cl); proficiency testing achieves z-scores ≤1.2 SWGDRUG Round 57. Economic 62% premium reduction versus DEA-exempt CRMs positions for EMA Ph. Eur. 2.2.46 chiral monograph development and CDC NSQAP participation.

Ordering, Availability & Fulfillment

Strategic inventory sustains PCI-DSS 4.1 WooCommerce processing (3DS 2.2 mandate) across global payment vectors (<12h throughput). DHL Express/FedEx Clinical Pak neutral transit (97% 2-5 day AOE) incorporates CN23/HAWB Schedule 1 declarations. Volume escalators trigger 25+ blister (-15%), 100+ (-28%) schedule; eCOA distributed ledger timestamps. JDA RedPrairie 99.8% FC attainment; dedicated researchchemdesk@domain resolves EAR/ITAR preclearance 24/7/365.

Legal & Regulatory Disclaimer

Flubrotizolam (FANAX) 0.5mg (CAS 57801-95-3) designated strictly for laboratory research purposes only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications. Purchasers warrant comprehensive jurisdictional compliance; seller indemnified against diversion/misapplication per UCC §2-316(3)(b). Compulsory end-user verification precedes release.